Drugs / HLA-A*2402 or A*0201 restricted peptides
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01949688 | Jun 2010 → Mar 2019 | cancer | Shiga University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLA-A*2402 or A*0201 restricted peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01949688 ↗ |
| Modality | Vaccine | “vaccine treatment” NCT01949688 ↗ |
| Route | Subcutaneous | “vaccinated subcutaneously once a week” NCT01949688 ↗ |